UQBA KHAN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology BROOKLYN, NY NPI 1780923920
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NY Acerta Pharma LLC All categories
General Payments — all program years on this page
$20,714.10
- Category: General Payments
- Program years: PY2018–2024
- Record count: 42
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $4,503.42 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,132.50 | 3 |
| Travel and Lodging | $227.04 | 2 |
| Food and Beverage | $143.88 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $4,503.42 | 8 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1104222809 | AstraZeneca Pharmaceuticals LP | $47.37 | 10/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1104367307 | AstraZeneca Pharmaceuticals LP | $525.00 | 05/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1104385141 | AstraZeneca Pharmaceuticals LP | $525.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1104402387 | AstraZeneca Pharmaceuticals LP | $179.67 | 10/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1104762278 | AstraZeneca Pharmaceuticals LP | $27.70 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1104764452 | AstraZeneca Pharmaceuticals LP | $3,082.50 | 10/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1105861626 | AstraZeneca Pharmaceuticals LP | $38.04 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105900200 | AstraZeneca Pharmaceuticals LP | $78.14 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.